Phase 2 Liver Cancer Trial, Recruiting NCT06261814 Sponsor: john eisenbrey Condition: Liver Cancer
Back to Liver Cancer

Phase 2 Liver Cancer Trial, Recruiting

NCT06261814
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are scheduled to receive TACE (a procedure that delivers treatment directly to a liver tumour) for a liver tumour
  • People who are at least 18 years old
  • People who are in a stable medical condition
  • Women of childbearing age who have a negative pregnancy test result
  • People who have given their signed agreement to take part in the study

Who may not be able to join:

  • People who are medically unstable, seriously or terminally ill, or whose medical condition is difficult to predict
  • People who are known to have sensitivities or allergic reactions to the ingredients in Lumason (a contrast agent used in ultrasound imaging)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 215-503-5188

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
john eisenbrey
Registry
ClinicalTrials.gov
Start date
7 August 2024
Est. completion
1 July 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Recurrence; Sensitivity; Specificity; Positive predictive value; Negative predictive value; False discovery rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov